850 related articles for article (PubMed ID: 19166419)
1. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
2. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
5. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.
Tang HL; Li Y; Hu YF; Xie HG; Zhai SD
PLoS One; 2013; 8(4):e62162. PubMed ID: 23646118
[TBL] [Abstract][Full Text] [Related]
7. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
[TBL] [Abstract][Full Text] [Related]
10. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Nakagawa K; Sugimura H; Ohashi K; Ishizaki T
Pharmacogenetics; 2001 Jun; 11(4):341-8. PubMed ID: 11434512
[TBL] [Abstract][Full Text] [Related]
11. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 polymorphism influences Helicobacter pylori eradication.
Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
15. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
[TBL] [Abstract][Full Text] [Related]
16. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
Suzuki T; Matsuo K; Sawaki A; Wakai K; Hirose K; Ito H; Saito T; Nakamura T; Yamao K; Hamajima N; Tajima K
Epidemiol Infect; 2007 Jan; 135(1):171-6. PubMed ID: 16740190
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
[TBL] [Abstract][Full Text] [Related]
18. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
[TBL] [Abstract][Full Text] [Related]
19. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Jul; 80(1):41-50. PubMed ID: 16815316
[TBL] [Abstract][Full Text] [Related]
20. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
Zhang L; Mei Q; Li QS; Hu YM; Xu JM
J Clin Pharm Ther; 2010 Dec; 35(6):713-22. PubMed ID: 21054464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
